Pharmaceuticals: buprenorphine dilaudid methadone morphine demerol codeine oxycodone hydrocodone fentanyl; Brand names: Oxycontin Percodan Percocet Vicodan Tylenol #3 Tylenol #4 Darvon Darvocet Stadol Nubaine Ultram Meperidol Duragesic; Street drugs: smack horse H percs oxys dope

 

home
about us
locations
treatment program
video
learn more
resources
contact us
sitemap
search this site:
 

CURRICULUM VITAE

NAME: Rahim Shafa
DATE OF BIRTH:  May 9, 1957
PLACE OF BIRTH: Iran
CURRENT POSITION: Scientific Director, Metro West & Greater Boston CRC
Metro West & Greater Boston CNS Research Center
215 West Street, P.O. Box, 298 Milford, MA 01757
PRIVATE PRACTICE: Director, Novel Clinical Psychopharmacology Care
67 Union Street, MOB-S107 Natick, MA 01760
EDUCATION:   
  1982 M.D. National University of Iran, Tehran, Iran
  1997 B.C. American Board of Adult Psychiatry & Neurology
  2003 W.C.  American Academy of Addiction Psychiatry
Buprenorphine outpatient maintenance program
POSTDOCTORAL TRAINING:
  Internship and Residencies:
  1990-1991 Psychiatric Intern (Wilmington Hospital, Delaware State Hospital), Jefferson University, Wilmington, DE.
  1991 Psychodynamic Training; Child & Adolescent Development & Disorders; Conflict Between Men and Women; Eating Disorders, Philadelphia Psychiatric Institute (evening courses); Philadelphia, PA.
  1991-1992 PGYII, Inpatient Psychiatry, (Solomon Carter Fuller Mental Health Center, University Hospital), Boston University, Boston, MA.
  1992-1993 PGYIII, Outpatient Psychiatry (Psychosomatic Clinic, Boston City Hospital, VA Bedford) Boston University, Boston, MA.
  1993-1994 Chief Resident, Consultation Liaison, Boston City Hospital Medical Psychiatry, Boston University Medical Center, Boston, MA.
  Fellowships:  
  1994-1998 Research Fellow, Commonwealth Research Center, Massachusetts Mental Health Center, Harvard Medical School, Boston, MA.
  1995-1998  VA Special Fellow in Clinical Pharmacology, Brockton  VA Medical Center, Harvard South Shore Psychiatry Residency Program, Harvard Medical School, Brockton, MA.
  March 2000 BCT Certificate, Columbia School of Physicians and Surgeons, NY.
  January 2003 Buprenorphine Management of Opioid Dependence, American Academy of Addiction Psychiatry.
LICENSURE AND CERTIFICATION:
  1982 Iran Board of Registration in Medicine
  1985  Licensed General Practitioner, British General Council
  1992  Massachusetts Board of Registration in Medicine
  1993 California Board of Medical Quality Assurance
  1997 Board Certified in adult Psychiatry & Neurology
  1997 Instructor, Intensive Diagnostic Interview, Oral Review Board Exam Preparatory Course, Massachusetts Mental Health, Harvard Medical School
  1998  Certified in Clinical Pharmacology Research Harvard Medical School
  2000 Certified in ECT, Columbia School of Physicians and Surgeons, New York, NY
  2003 Waiver Certificate, Buprenorphine Outpatient Maintenance Program, American Academy of Addiction Psychiatry
ACADEMIC APPOINTMENTS:
  1985-1987 Director of Continuing Medical Education, National Iran Oil Co., (NIOC), Tehran, Iran
  1991-1993  Psychiatry Resident, Boston University School of medicine, Boston, MA.
  1993-1994 Chief Resident in Psychiatry, Boston University Medical Center, Medical Psychiatry Unit at The University Hospital & Chief Resident in Consultation Liaison Services at Boston City Hospital, Boson, MA.
  1994-1998 Research Fellow Psychopharmacology, Harvard Medical School, Boston, MA.
  1996-1998  Senior Fellow, Clinical Research in Psychiatry, Harvard Medical School, Commonwealth Research Center, Clinical Research and Evaluation Unit (CREU), Massachusetts Mental Health Center, Boston, MA.
  1998-1999 Clinical Instructor in psychiatry, Staff Psychiatrist Geri/Med- Psych. Unit, Cambridge Health Alliance, Somerville Hospital, Harvard Medical School, Somerville, MA.
  1998-2001 Consultant in Clinical Research; Implementation of Clinical Trials, Subject Recruitment, Subject Retainment & Follow-up, Harvard Medical School, Commonwealth Research Center, Massachusetts Mental Health Center, Boston, MA.
  1998-2001 Clinical Investigator & Clinical Instructor in Psychiatry, Harvard Medical School, Commonwealth Research Center, Massachusetts Mental Health Center, Boston, MA.
  2001-Present Scientific Director, Metro West  CNS Research Center, 57 Union Street, MOB-S 107, Natick, MA.
HOSPITAL APPOINTMENTS:
  1982-1984 Medical Director, Lieutenant Commander, Dept. of Health & Medical Education, Jen d'Armory of Iran, Chabahar, Iran.
  1984-1986 Medical Director, Industrial Medicine & Director, Emergency Medicine, Industrial Island Hospital, National Iran Offshore Oil Company, Iran.
  1986-1987 Vice President & Deputy Medical Director, Iraj (the Head Quarter) General Hospital, National Iran Oil Co., Tehran, Iran.
  1994-1998   Research Fellow, Commonwealth Research Center, Massachusetts Mental Health Center, Boston, MA.
  1998-1999 Teaching Faculty & Staff Psychiatrist, Cambridge Health Alliance, Somerville Hospital.
  1998-2001 Consultant in Clinical Research, Commonwealth Research Center, Massachusetts Mental Health Center, Boston, MA.
  1999-2001 Medical Director, (Community Psychiatry) at Wayside Youth & Family Support Network, 118 Lincoln Street, Framingham, MA.
  1997-Present Staff  Psychiatrist, Metro West Medical Center, Leonard Morse Hospital, Natick MA.
  2000-Present Principal Investigator in Psychiatric Research & Clinical Psychopharmacology, Dept. of Psychiatry, Tenet Metro West Medical Center, Leonard Morse Hospital, Natick MA.
OTHER PROFESSIONAL POSITIONS AND MAJOR VISITING APPOINTMENTS
  1984-1986 Associate Director, Dept., of Industrial Medicine & Public Health, Central & five Satellite Offshore Clinics, National Iran Offshore Oil Company, Iran.
  1986-1987 Associate Dir4ector, Dept. of Industrial & Public Health, Iran General Hospital, National Iran Oil Company, Iran.
  1987-1990  Instructor in Basic Medical Sciences, Stanley H. Kaplan Educational Center, San Diego, CA
  1988-1990 Medical Examiner, Equifax Services, Inc., San Diego, CA
  1997-Present  Consultant Clinical Psychopharmacology, General Psychiatry, questions in regard to use of Alternative Medicine in Psychiatry, Dept. of Psychiatry Tenet Metro West Medical Center, Leonard Morse Hospital, Natick, MA.
  2003-Present  Psychiatric Research Staff, Walden Behavioral Care, the second Research Site for Metro West & Greater Boston CNS Research Center, Waltham, MA.
AWARDS AND HONORS:
  1982 Top 1% class of 1982, National University of Iran.
  1984  Recognition Award, for implementation of Cutaneous Leishmaniosis Vaccine, Iran.
  1994 Clinical Research Fellowship in Psychopharmacology, Commonwealth Research Center, Massachusetts Mental Health Center, Harvard Medical School, Boston, MA.
  (1995)
(1996)
(1997)  		 VA Grant Award Repeated Three Successive Years; 1995-1996,1996-1997 & 1997-1998, Grant Awarded in Research Fellowship in Clinical Pharmacology, Brockton VA Medical Center, Harvard Medical School, Harvard South Shore Psychiatry Residency Training Program, Brockton, MA.
  2000 "Who is Who", Strathmore's Honors for Leadership and Achievement in Medicine. (2000-2001)
  2002  "America's Top Psychiatrist", in (Psychopharmacology of Anxiety and Mood Disorder) recognized by "Consumers Research Council of America", an independent report in Recognition of Individual Professionals Accomplishments in field of Psychiatry. (2002-2003)
MEMBERSHIPS IN PROFESSIONAL SOCIETIES:
  American Medical Association
  American Psychiatric Association
  American Society of Clinical Psychopharmacology
  American Academy of Addiction Psychiatry
  American Association for The Advancement of Science
  Massachusetts Medical Society
  Massachusetts Psychiatric Society
  NAMI (National Association for Mentally Ill)
  New York Academy of Science
  IAMA (Iranian American Medical Associations)
  Iran Medical Council
  British General Council
SELF REPORT OF TEACHING:
  1993 Chief Resident, supervised psychiatry residents, Consultation & Liaison Psychiatry, Boston City Hospital, Boston, MA.
  1994 Chief Resident, provided tutoring and supervised medical students and residents in psychiatry, Medical Psychiatry Unit, University Hospital, Boston University, Boston, MJA.
  1997-2001 Instructor, Intensive Diagnostic Interview, a preparatory Course for the Oral Review Board Exam in Psychiatry, Mass. Mental Health Center, Harvard Medical School, Boston, MA.
ADVISORY RESPONSIBILITIES:
  Member of advisory panel and speakers bureau, Astra Zenaca.
  Member of advisory panel and speakers bureau, Janssen.
  Member of advisory panel and speakers bureau, Bristol-Myers-Squibb.
  Member of advisory panel and speakers bureau, GlaxoSmithKline.
  Member of advisory panel and speakers bureau, Eli Lilly and Company.
ACCOUNT OF LEADERSHIP:
  1980-1983  Doctors for Free Medical Care (Doctors Without Borders), prepared groups of medical professionals (mainly from the medical school faculty),  arranged trips, and provided free medical service to the most deprived communities, Iran.
  1981-1982 Medical Student Volunteer: Community Services, Instructor for CPR courses for the public, Taleghani Hospital, Eveen, Iran.
  1982-1984 Devised, Supervised & Implemented Training Curriculum for paramedics in military, (Accredited by Iran's Ministry of Health to issue certificate), Jen d'Armory, Army of Iran, Chabahar, Iran.
  1982-1984 Designed  & Taught Algorithms for diagnosis & treatment of endemic diseases and emergency care for military paramedics, Chabahar, Iran.
  1982-1984 Designed CME workshops and training courses for Medical Personnel in the Military, (especially the paramedics) Army of Iran, Chabahar, Iran.
  1984-1987 Devised, Supervised & Implemented In-Service & CME Training courses for paramedics, physician assistants, nurses and nurse practitioners, National Iran Oil Company, Tehran, Iran.
  1987 Director of CME courses for physicians, NIOC, Tehran, Iran (The department consisted of 17 general hospitals and 25 satellite clinics).
  1988-1990  Designed Basic Science Lecture Series, (preparatory courses for FMGEMS, FLEX & NMB Examinations) and taught peer physician, Stanley H. Kaplan,  San Diego, CA.
  1993-1994 Chief Resident, Boston City Hospital, University Hospital, Boston University, Boston, MA.
  1994-2000 Clinical Investigator / Lead Recruiter investigation of novel Antipsychotics, clinical psychopharmacology, Mass. Mental Health Center, Harvard Medical School, Boston, MA.
  2001-present Principal Investigator and President of Metro West and Greater Boston Research Center, 215,West Street, Milford, MA.
CLINICAL RESEARCH EXPEREINCE:
  1994-present CLINICAL INVESTIGATOR:
 
  •      Phase II Study, Safety and Efficacy of OPC 14597, an Inpatient antipsychotic trial.
  •      Phase II Study, Safety and Efficacy of Ziprasidone, an Inpatient antipsychotic trial.
  •      Phase III Study, dose range and Safety and Efficacy of OPC-14597, inpatient trial.
  •   Phase III Study, Ziprasidone, Outpatient Antipsychotic Trial.
  •    Phase I Study, Pharmacokinetics Study of IM Ziprasidone, Inpatient Trial.
  •   Phase III Study, Clinical Outcome & Service Utilization, an Outpatient trial of Quetiapine.
  •   Phase II Study and Efficacy of MDL100,907 an inpatient antipsychotic trial.
  •     Phase III Study, comparing Efficacy of Aripiprazole vs. Risperidone, inpatient trial.
  •     Phase III Study, Dose Range and Efficacy Study of MDL 100,907 inpatient study.
  •     Clozapine Response & Biogenic Amines in the Treatment of Refractory Schizophrenia, inpatient study.
  •    Clozapine Response & Biogenic Amines in the Treatment of Refractory Schizophrenia, inpatient study.
  •     Clozapine Response in treatment of  First Episode Schizophrenia, inpatient & outpatient study.
  •      Clinical Efficacy of Olanzapine in treatment of First Episode Schizophrenia, an inpatient stabilization and outpatient follow up study.
  •     Quality of Life and Clinical Utilization Outcome of Treatment with Clozapine comparing to Olanzapine an outpatient trial.
  •      Study of Prolactin changes in response to treatment with Clozapine in First Episode Schizophrenia.
  •      "INTERSEPT" International study of Suicide &Y Schizophrenia in response to Clozapine, a double blind randomized, open label comparison outpatient trial of Clozapine vs. Olanzapine.
  •      Norepinephrine changes in Response to Clozapine treatment in First Episode Schizophrenia.
  •      Cognitive changes in response to treatment with Clozapine in refractory schizophrenia.
  •     An inpatient with outpatient follow up, single blind, active control study of efficacy of xxxxxx (comparing two atypical antipsychotics) in treatment and prevention of suicide in schizophrenia, 1997-2002.
  •     Several numbers of other (Phase II and/or/Phase III) protocols; inpatient/outpatient double blind, placebo controlled, study of safety, tolerability and efficacy of xxxxxx or xxxxxx (variety of novel antipsychotics) in treatment of chronic schizophrenia, 1994-1999.
  1999-present   PRINCIPAL INVESTIGATOR
 
  •      An inpatient double blind placebo control fix dose study of safety and efficacy of xxxxxx (a novel antipsychotic) in treatment of acute Bipolar Mania, 1999-2001.
  •     An outpatient double blind placebo control dose ranging study of efficacy of xxxxx (a novel antipsychotic) in stabilization, maintenance and relapse prevention of Bipolar Mania, 1999-2002.
  •      An  outpatient double blind placebo control dose ranging study of safety, tolerability and efficacy of xxxxx (an antidepressant) in treatment of adolescents with major depression, 1999-2001.
  •     An outpatient blindly randomized open label Phase IV study of long-term safety and morbidity of xxxxx (a novel antipsychotic vs two other novel antipsychotics) in treatment of schizophrenia, 2001-2002
  •     An inpatient double blind, placebo control study of safety, tolerability and efficacy of xxxxx (an antiepileptic) in treatment of acute Bipolar Mania, 1999-2001).
  •     An outpatient double blind study of mono-therapy vs. two arms of combination therapy xxxxxx & xxxxxx (an antidepressant combined with an antipsychotic), in treatment of Bipolar Depression, 1999-2001).
  •     A Phase III, randomized, placebo-controlled, double-dummy study evaluating the safety and efficacy of oral xxxxxx (novel antipsychotic) vs. xxxxx (a conventional antipsychotic) and placebo in inpatients with an acute manic episode, 2001-2003.
  •     Comparison fasting triglyceride levels in cohort with schizophrenia and related disorders treated chronically with xxxxx,xxxxxx (novel antipsychotics and typical antipsychotics) 2001.
  •    The assessment of xxxxxx (a stimulant) for treatment of xxxxxx (novel antipsychotic) associated weight gain inpatients with schizophrenia, related disorders and Bipolar Disorder, 2001-2003.
  •     The xxxxx (a novel antipsychotic) observational study of cardiac outcome, simple large trial, an open label blindly randomized multinational study, 2002-Present.
  •     A case control investigation exploring the relationship between gene variants (xxx markers) and agranulocytosis or granulocytopenia in adult patients treated with xxxxxx (an atypical antipsychotic), 2002-Present.
  •     A Phase I Study of  "Comparison of Steady-State Pharmacokinetics of xxxx (Novel Antipsychotic) after Extended-Release xxx xxxx (Novel Antipsychotic) xx mg  and Immediate-Release Oral xxxx (an Existing Novel Antipsychotic xx mg. b.i.d. in Subjects with Schizophrenia or Schizoaffective Disorder", 2003-2004.
MAJOR RESEARCH INTERESTS
  Endo-Neuropsychopharmacology & Immunology
  Pharmacogenomics & Chronic Mental Illness
  Biology of Psychosis & Disturbance of Cognition
  Biology of Reward System & Dual Diagnosis
  Treatment Outcome Studies
PUBLICATIONS:
Shafa, R. Management of Burn Victims.  NIOC Medical Letter 85:40-44, 984.
Shafa, R. Safety Points in Air Transportation of Wounded Victims.  NIOC Medical Letter 101:11-15, 1986.
Shafa, R. Means of Stress Reduction.  NIOC Medical Letter 120:12-18, 1587.
Shafa, R. Role of Stress in Provoking Complications in Wound Healing.  NIOC Medical Letter 120:34-36, 1987. 
Patel, JK., Shafa, R,. Danzler, A., Salzman, C.  Drug Metabolism Cytochrome P-450 Enzymes, in preparation.
Patel, JK., Shafa, R., Canuso, C., Kalinowski, AG., Schildkrout, JJ., Green, AI.  Effects of Risperidone and Clozapine on Hyperprolactinemia and Prolactinoma in Chronic Psychosis, in preparation.
Shafa, R., Patel, JK., Green, AI.  Re-challenge with Clozapine After Prior Long-term Use: Cardiovascular Symptoms, in preparation.
Patel, JK., Shafa, R., Khan, A.  Cytochrome P450, Ethnicity and Drug Metabolism in preparation.
PRESENTATIONS:
Patel, JK., Shafa, R., Khan, A. Cytochrome P-40 Ethnicity and Drug Metabolism Mass DMH Symposium, Multicultural Advisory Committee for Professionals of Color, October, 1995.
Shafa, R., Patel, JK., Kalinowski, A., Schildkrout, JJ., Green, AI.  "Pituitary Microadenoma, Risperidone and Clozapine".  Poster presented at American Psychiatric Association Annual Meeting, May, 1996.
Dooley, P., Patel, JK., Kalinowski, AG., Shafa, R., Canuso, C., Green, AI.  Recruitment for Psychopharmacological Studies in Schizophrenia: Gender Differences.  Poster presented at the American Psychiatric Association, Annual Meeting, May 1996.
Stone, WS., Seidman, LJ., Kalinowski, AG., Shagrin, B., Patel, JK., Shafa, R., Canuso, C., Schildkraut, JJ., Green, AI.  "Effect of Clozapine on Cognitive Functions in Treatment- Refractory  Schizophrenia".  Poster submitted to V. International Congress on Schizophrenia Research, 1997.
Shafa, R., Patel, JK., Kalinowski, AG., Green, AI.  "Re-challenge with Clozapine:  Cardiovascular Symptoms".  Poster submitted for American Psychiatric Association, Annual Meeting, May 1997.
Shafa, R., Powsner, R., Fischman, AJ., Verna, S.  "Brain Imaging and Positive Symptoms During a First Episode of Schizophrenia".  Poster presented in Harvard Research Day, March 1997.
OTHER WRITTEN MATERIAL:
Shafa, R. Platonic Love:  A Discussion of the Implications of Platonic Love on One's Mental Health.  University Press, Tehran, Iran, 1977 (National University of Iran Medical Library).
Shafa, R.  Dissertation:  Hysteria (Dissociative and Conversion Disorders) an Overview of Etiology, Clinical Manifestations and Treatment, 1982.  (National University of Iran Medical Library).
 
back to:
> Locations
 

1.800.978.0808     ::     1.856.663.4447     ::     1.856.488.6380 (fax)